AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease Biotech Investing
Bausch Health Commences Cash Tender Offer For Any And All Of Its 7.00% Senior Secured Notes Due 2024 Medical Device Investing
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Conditional Redemption Of Existing Senior Secured Notes Medical Device Investing
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction Adenocarcinoma Pharmaceutical Investing
Bristol Myers Squibb Presents New Data at Digestive Disease Week® on Zeposia Highlighting Clinical Benefits and Safety Profile in Patients with Ulcerative Colitis Biotech Investing
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo plus Yervoy for Treatment of Mismatch Repair Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer After Prior Chemotherapy Biotech Investing
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS in Subjects with Lupus Nephritis Biotech Investing
U.S. Food and Drug Administration Approves Opdivo® as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy Biotech Investing
Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors Biotech Investing
Merck Announces Positive Topline Results from PNEU-DIRECTION and PNEU-PLAN Phase 3 Pediatric Studies for V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine Pharmaceutical Investing
Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY® Pharmaceutical Investing
